Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-209 in Essential Hypertension
NCT05631990Phase 2Completed
- Sponsor
- Addpharma, Inc.
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amlodipine, chlorthalidone and telmisartan in essential hypertension (4 arms), sponsored by Addpharma, Inc. Primary endpoint: Change rate of Mean Sitting Systolic Blood Pressure at 8 weeks. Started Apr 2023; status: completed.
02
Drugs
amlodipinechlorthalidonetelmisartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05631990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631990.